AlJasser Reham, AlAqeely Razan, AlKenani Manal, AlQahtani Sadeem, AlZahrani Afnan, Lambarte Rhodanne
Department of Periodontics and Community Dentistry, Dental College, King Saud University, 11545 Riyadh, Saudi Arabia, Arabia.
Saudi Board of Periodontics Program, 12211 Riyadh, Saudi Arabia.
Saudi J Biol Sci. 2022 Jan;29(1):148-153. doi: 10.1016/j.sjbs.2021.08.079. Epub 2021 Aug 28.
To evaluate and compare changes in salivary flow rate and salivary levels of TIMP-1 and TIMP-2 in individuals taking oral Isotretinoin (INN) with those who do not take INN. To assess the variation in TIMP-1 and TIMP-2 as well as salivary flow rate observed at different stages of periodontal disease in comparison to those observed in the case of healthy periodontium.
An examiner-blind case-control study involving 180 human adults divided into six groups based on their periodontal status. Clinical parameters, including pocket depth, clinical attachment level, and bleeding on probing were measured at six sites per tooth. Whole unstimulated saliva samples were collected from all subjects to evaluate salivary flow rate (SFR). Salivary TIMP-1 and TIMP-2 levels were detected using enzyme-linked immunosorbent assay (ELISA). Data were analyzed using IBM SPSS Software. The Kruskal Wallis test and Mann-Whitney U-tests were employed to verify any significant differences between the groups for all parameters. Multi-regression analysis was performed for each parameter tested in each group. All tests were compared at a significance level of 0.05.
SFR was statistically significantly lower among all INN groups in comparison to the control groups ( < 0.001). TIMP-1 and TIMP-2 were significantly higher in all INN groups in comparison to the control groups, in both gingivitis cases ( = 0.004, < 0.0001 respectively) and periodontitis cases ( < 0.0001).
Although INN reduces salivary flow rate, the findings of the present study revealed that it had an anti-inflammatory effect in periodontal biomarkers. Specifically, it was positively correlated with an elevation of salivary TIMP-1 and TIMP-2. Hence, INN might be a future additive medication to be further evaluated for the treatment of periodontal diseases.
评估并比较服用口服异维A酸(国际非专利药品名称)的个体与未服用异维A酸的个体的唾液流速以及唾液中基质金属蛋白酶组织抑制因子-1(TIMP-1)和基质金属蛋白酶组织抑制因子-2(TIMP-2)水平的变化。评估与健康牙周组织相比,在牙周疾病不同阶段观察到的TIMP-1和TIMP-2以及唾液流速的变化。
一项 examiner-blind 病例对照研究,纳入180名成年人类,根据其牙周状况分为六组。在每颗牙齿的六个部位测量临床参数,包括牙周袋深度、临床附着水平和探诊出血。从所有受试者收集未刺激的全唾液样本以评估唾液流速(SFR)。使用酶联免疫吸附测定(ELISA)检测唾液中 TIMP-1 和 TIMP-2 的水平。使用 IBM SPSS 软件分析数据。采用 Kruskal Wallis 检验和 Mann-Whitney U 检验来验证所有参数在各组之间是否存在任何显著差异。对每组测试的每个参数进行多元回归分析。所有测试均在显著性水平0.05下进行比较。
与对照组相比,所有异维A酸组的唾液流速在统计学上显著更低(<0.001)。在牙龈炎病例(分别为 =0.004,<0.0001)和牙周炎病例(<0.0001)中,所有异维A酸组的 TIMP-1 和 TIMP-2 均显著高于对照组。
尽管异维A酸会降低唾液流速,但本研究结果表明它在牙周生物标志物方面具有抗炎作用。具体而言,它与唾液中 TIMP-1 和 TIMP-2 的升高呈正相关。因此,异维A酸可能是未来用于治疗牙周疾病有待进一步评估的附加药物。